CJC-1295 (no DAC) vs Epitalon
Both CJC-1295 (no DAC) and Epitalon are used for anti-aging. Here's how their evidence, dosing, and regulatory status actually compare.
CJC-1295 (no DAC)
Evidence BModified Growth Hormone Releasing Factor 1-29
A growth hormone releasing hormone (GHRH) analog most commonly stacked with Ipamorelin to stimulate natural GH pulsatile release without disrupting the hypothalamic axis.
View full CJC-1295 (no DAC) profile →Epitalon
Evidence C+Epitalon (Epithalon, AEDG)
A synthetic tetrapeptide that reportedly upregulates telomerase activity. Russian longevity studies suggest mortality reductions but Western RCTs are absent.
View full Epitalon profile →Side-by-Side
| Attribute | CJC-1295 (no DAC) | Epitalon |
|---|---|---|
| Evidence Grade | B | C+ |
| FDA Status | Not FDA-approved — Category 1 (compounding allowed) | Not FDA-approved — Russian-origin research peptide |
| Typical Dose | 100–300 mcg before bed (subcutaneous) | 5–10 mg daily for 10–20 days, cycled (subcutaneous) |
| Clinics Indexed | 156 | 47 |
| Categories | growth-hormone, anti-aging, recovery | anti-aging, longevity |
Key reported benefits — CJC-1295 (no DAC)
- ✓Growth hormone release
- ✓Fat loss
- ✓Improved sleep
- ✓Muscle recovery
Key reported benefits — Epitalon
- ✓Telomerase upregulation (preclinical)
- ✓Sleep/circadian normalization
- ✓Anti-aging signals
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.